ALLO‐605 is a next‐generation AlloCAR T investigational therapy that targets the B‐cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma and other BCMA‐positive malignancies, which incorporates Allogene's proprietary TurboCAR technology to allow for cytokine activation signalling to be engineered selectively into CAR T cells. Here, TNFRSF17 is linked to AL amyloidosis.